RxDoctor Payments Data

Steven Beaudette, MD

Cardiovascular Disease · Nashua, NHNPI 1265418594

Payments from drug & device makers

$730in general payments, 2019–2025

Across 12 payments — averaging $60.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$299
  • Medtronic$121
  • Pfizer$105
  • Boston Scientific$100
  • Lantheus Medical Imaging, Inc.$42
  • Johnson & Johnson$24
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$730100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$730 in reported general payments places this provider in the 45th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$153,215
Medicare patients
1,831
Services billed
3,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban310$390,926
XareltoRivaroxaban61$55,433
EntrestoSacubitril/Valsartan41$48,495
VascepaIcosapent Ethyl25$12,131
Metoprolol Succinate607$8,523
Ezetimibe217$5,950
Rosuvastatin Calcium292$4,971
Atorvastatin Calcium481$4,262
Torsemide87$3,024
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,214
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$2,136
Isosorbide Mononitrate ErIsosorbide Mononitrate149$1,893
Flecainide Acetate21$1,884
Potassium Chloride105$1,844
Amiodarone Hcl38$1,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$105$390,926310 claims
Johnson & JohnsonXarelto$24$55,43361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 112 cardiovascular disease providers in New Hampshire.

Other cardiovascular disease in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →